Next Article in Journal
IL-23 and Th17 Disease in Inflammatory Arthritis
Next Article in Special Issue
Measurement of Respiratory Chain Enzyme Activity in Human Renal Biopsy Specimens
Previous Article in Journal
The Fragility Index in a Cohort of Pediatric Randomized Controlled Trials
Previous Article in Special Issue
Statins, Muscle Disease and Mitochondria
Article Menu
Issue 8 (August) cover image

Export Article

Open AccessFeature PaperArticle
J. Clin. Med. 2017, 6(8), 80; doi:10.3390/jcm6080080

Use of FGF-21 as a Biomarker of Mitochondrial Disease in Clinical Practice

1
Department of Clinical Biochemistry, Oxford University Hospitals, Oxford OX3 9DU, UK
2
Department of Paediatrics, The Children’s Hospital, Oxford OX3 9DU, UK
3
Department of Neuropathology and Ocular Pathology, West Wing, Oxford University Hospitals, Oxford OX3 9DU, UK
4
Sir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, UK
5
Department of Neuroradiology, West Wing, Oxford University Hospitals, Oxford OX3 9DU, UK
6
NHS Specialised Services for Rare Mitochondrial Disorders of Adults and Children UK, Oxford Medical Genetics Laboratories, Oxford University Hospitals, Oxford OX3 7LE, UK
7
Nuffield Department of Obstetrics and Gynaecology, University of Oxford, Oxford OX3 9DU, UK
*
Author to whom correspondence should be addressed.
Academic Editor: Iain Hargreaves
Received: 19 June 2017 / Revised: 29 July 2017 / Accepted: 2 August 2017 / Published: 21 August 2017
View Full-Text   |   Download PDF [1337 KB, uploaded 21 August 2017]   |  

Abstract

Recent work has suggested that fibroblast growth factor-21 (FGF-21) is a useful biomarker of mitochondrial disease (MD). We routinely measured FGF-21 levels on patients who were investigated at our centre for MD and evaluated its diagnostic performance based on detailed genetic and other laboratory findings. Patients’ FGF-21 results were assessed by the use of age-adjusted z-scores based on normalised FGF-21 values from a healthy population. One hundred and fifty five patients were investigated. One hundred and four of these patients had molecular evidence for MD, 27 were deemed to have disorders other than MD (non-MD), and 24 had possible MD. Patients with defects in mitochondrial DNA (mtDNA) maintenance (n = 32) and mtDNA rearrangements (n = 17) had the highest median FGF-21 among the MD group. Other MD patients harbouring mtDNA point mutations (n = 40) or mutations in other autosomal genes (n = 7) and those with partially characterised MD had lower FGF-21 levels. The area under the receiver operating characteristic curve for distinguishing MD from non-MD patients was 0.69. No correlation between FGF-21 and creatinine, creatine kinase, or cardio-skeletal myopathy score was found. FGF-21 was significantly associated with plasma lactate and ocular myopathy. Although FGF-21 was found to have a low sensitivity for detecting MD, at a z-score of 2.8, its specificity was above 90%. We suggest that a high serum concentration of FGF-21 would be clinically useful in MD, especially in adult patients with chronic progressive external ophthalmoplegia, and may enable bypassing muscle biopsy and directly opting for genetic analysis. Availability of its assay has thus modified our diagnostic pathway. View Full-Text
Keywords: fibroblast growth factor-21; FGF-21; mitochondrial disease; diagnosis fibroblast growth factor-21; FGF-21; mitochondrial disease; diagnosis
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Morovat, A.; Weerasinghe, G.; Nesbitt, V.; Hofer, M.; Agnew, T.; Quaghebeur, G.; Sergeant, K.; Fratter, C.; Guha, N.; Mirzazadeh, M.; Poulton, J. Use of FGF-21 as a Biomarker of Mitochondrial Disease in Clinical Practice. J. Clin. Med. 2017, 6, 80.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Clin. Med. EISSN 2077-0383 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top